Update to BioSenic and Phebra deal

Belgian biotech BioSenic (Euronext: BIOS) has reached agreement on a binding term sheet with privately-held Australian firm Phebra on the development of the first oral formulation of arsenic troxide for chronic graft versus host disease (cGvHD) treatment.

A new binding term sheet has been signed to adapt the terms of two previous agreements under which Phebra granted Medsenic -a subsidiary of BioSenic - an exclusive worldwide license agreement with a first marketing and distribution agreement (MDA) for OATO (oral arsenic trioxide) in the field of several targeted autoimmune diseases.

"The radical improvement in the commercial agreement between Phebra and Medsenic should facilitate our task of implementing all the necessary funding for the few years of the cGvHD Phase III trial"The initial license agreement, signed in May 2021, provided a commercialization agreement of 100% net profits for Medsenic, mainly in Europe and 55% net sales profit for Phebra in the rest of the world, including major markets such as the USA, Canada, South America, Japan, South East Asia, China and Australia.